Demyelinating disease and cutaneous lymphocitic vasculitis after etanercept therapy in a patient with rheumatoid arthritis.
Martínez-Taboada
V M
VM
Val-Bernal
J F
JF
Pesquera
L C
LC
Fernández-Llanio
N E
NE
Esteban
J M P
JM
Blanco
R
R
Alonso-Bartolome
P
P
Gonzalez-Vela
C
C
Rodríguez-Valverde
V
V
D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000150:complications*; D003711:Demyelinating Diseases / Q000139:chemically induced*; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects*; D007279:Injections, Subcutaneous / Q000009:adverse effects; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor; D018366:Vasculitis, Leukocytoclastic, Cutaneous / Q000139:chemically induced*
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept